Treatment Advances

December 31, 2024

Review new data presented at ASH about nemtabrutinib, a once-daily, noncovalent, reversible BTK inhibitor. Clinical trials ongoing and recruiting patients.

November 25, 2024

Do prior number of treatments and BTK inhibitor response affect CAR T-cell therapy success for MCL? Learn insights from Dr. Manali Kamdar.

November 19, 2024

Learn insights about how certain treatment combinations and a new scoring system impacted people with low-grade follicular lymphoma.

November 08, 2024

Explore an innovative trial using Azer-cel, an allogeneic CAR T-cell therapy, for relapsed DLBCL patients, focusing on safety and effectiveness.

October 29, 2024

If you are a person with advanced-stage follicular lymphoma who is starting their first treatment, learn how certain therapy options compare.

October 15, 2024

After three years since its original Phase III trial, lisocabtagene maraleucel (liso-cel) is still proving effective for relapsed/refractory DLBCL patients.

September 16, 2024

Learn about the challenges of treating DLBCL with central nervous system involvement, explore available treatment options, and discover the latest research.

August 29, 2024

CAR-T therapy side effects in DLBCL patients are rare after two weeks, but how long should patients be monitored?

August 13, 2024

Learn about R-CHOP, a chemoimmunotherapy regimen used to treat follicular lymphoma. Understand its effectiveness and what to expect during treatment.

July 22, 2024

Is age just a number? Dr. Julio Chavez shares multicenter findings on how CAR T therapy can be effective in those 80 and older.